Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.11) by 81.82 percent. This is a 66.67 percent increase over losses of $(0.60) per
